Navigation Links
wCareAssist™

ProductswCareAssist™
Company Care Fusion
Item wCareAssist™
Features 
  • Nursing Notes
  • Vital Signs
  • Intake & Output Capture
  • Simple, Logical Templates
  • Information Entered at Time of Collection
  • Real Time Patient Information Available Anywhere Within the Wireless Network
Description wCareAssist™ provides care management tools that support the nursing process. The caregiver inputs data such as vital signs and I&O information at the point of collection via easy to use on-line flow sheets. This design supports compliance with documentation requirements.

At the bedside, in the hall, or at the nursing station, wCareAssist™ is right there working for the caregiver, allowing them to document and chart as they go on a handheld device, tablet or laptop. All information is available in real time. There is no reason for a nurse to interrupt the patient care process. At the end of a shift, the caregiver is now able to provide an accurate, concise electronic patient report.

Info Care Fusion
Customer Service: (703) 714-0730
Web site: http://www.carefusion.com

Related medicine products :

1. Humphrey Atlas Corneal Topography Systems
2. Atlas Corneal Topography Systems
3. Computerized Optical Systems
4. Immage Immunochemistry Systems
5. Express Elyte Systems
6. Horizontal-Vertical (H/V) Lumbar Valve Systems
7. Lumboperitoneal Catheter and Shunt Systems
8. Novus Valve Systems
9. Advance Posterior Stabilized Total Knee Systems
10. ADVANCE Posterior Stabilized Total Knee Systems
11. MOST Options Systems - Straight Smooth
The HEMOCHRON Jr. Signature+ Microcoagulation System offers point-of-care monitoring with numerous features to meet the needs of each individual department, as well as the needs of regulatory complia
Inquire
...'000 tests per year through automatic scheduling a... processing up to 4 assays on 4 plates simultaneou...to presentation of the results, are controlled by ... tube rack) and 256 (POS-ID Linear Rack) samples c...
IMMULITE 2000 assays are designed for use with the IMMULITE 2000, a high-throughput, continuous random access immunoassay analyzer. IMMULITE 2000 offers testing efficiency through centralization, and
Medicine Products:
(Date:11/21/2008)... preterm labor , , FRIDAY, Nov. 21 (Heal...witch that activates the uterine muscles for contr...to therapies for preterm labor. , The molecule... surface of these uterine muscle cells, keeping th... researchers from Dartmouth Medical School in New ...
(Date:11/21/2008)...ate University College of Medicine research team l...w layer of regulation in the cell division cycle, ... way cancer begins. , Wang, an assistant profess...ne, said the findings will lead to an improved abi...gn of new drugs that kill cancer cells by inhibiti...
(Date:11/21/2008)...FirstCall/ -- Heska Corporation,(Nasdaq: HSKA )...ociety of,Security Analysts, 12th Annual Biotech ...08 at 1177 Avenue of the Americas, 2nd Floor in Ne...n at 9:35 a.m. Eastern Time (7:35 a.m.,Mountain T...r two weeks,following the presentation through a ...
(Date:11/21/2008)... future antibiotic resistance from widespread use ...- People with moderate to severe chronic obstructi...the frequency of exacerbations through a regular, .... , The study, published in the first issue fo... and Critical Care Medicine , found that twice-dai...
Breaking Medicine News(10 mins):Health News:Long-Term Erythromycin Cut COPD Complications 2
...aimed to prevent more sudden deaths than defibrill... defibrillators according to US scientists.// Rese...mpared such preventive strategies by food suppleme... computer-simulated community of 100,000 people th...
...and why some people are hairier than others may ha...s.// The molecular mechanisms that determine whic...es, deciding the body's hair pattern has been disc...niversity of Manchester. This study on mice will ...
...wo-thirds of the people in the US do not wash thei...t had been newly formed had conducted the survey o... that the participants had been chosen from around..., United Arab Emirates, India, Malaysia, and South...
...n commissioned by the Australian government states... might be an cost effective option to control// th...rt also stated that to have found the various prog...ive, but raised questions about the effectiveness ...
Other Medicine News:Health News:Health Experts In Australia Toy With The Idea Of Surgery for Controlling Obesity In Teenagers 2
(Date:11/20/2008)...NE RESULTS OF FIRST PHASE III TRIAL SHOW SIGNIFICA...EMENT IN DAILY FUNCTION, IN, ...if., and BRUSSELS, Belgium, Nov. 20 /PRNewswire-Fi... JAZZ ) and UCB (Euronext Brussels: UCB),announce... the first of two,Phase III pivotal clinical tria...
(Date:11/20/2008)... 20 Duska Therapeutics,... that it has submitted its,pivotal Phase 3 ATPace...l,Protocol Assessment (SPA) procedure with the U....ubject to securing an agreement with the FDA, Dusk...le-blind, placebo-controlled and randomized Phase ...
(Date:11/20/2008)...vember 20 The Scandinavian-based d...nced results of studies on its,lead antimicrobial...on, DC,the studies showed that the novel lytic p...fect, significantly better towards killing Staphyl...rketed gold standard drugs. In,addition to this i...
(Date:11/19/2008)...port basic findings on critical enzyme,s regulatio...t an array of disorders , , MEMPHIS, Tenn.,... St. Jude Children,s Research Hospital have gained... enzyme workhorses called calpains. , , As...tion in many cellular processes, including the mov...
Breaking Medicine Technology:Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 3Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 4Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 5Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 6Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3National Federation of the Blind to Award 24100 000 7690 1National Federation of the Blind to Award 24100 000 7690 2Inspirational Medical Teachers Honored with Mentor Awards from the American Society of Hematology 7685 1Inspirational Medical Teachers Honored with Mentor Awards from the American Society of Hematology 7685 2ASH Holds a Special Symposium to Interest High School Students in Biomedical Research 2082 1ASH Holds a Special Symposium to Interest High School Students in Biomedical Research 2082 2New choices for patients 3A Transfusion free medicine for Jehovahs Witnesses and transfusion wary 7681 1New choices for patients 3A Transfusion free medicine for Jehovahs Witnesses and transfusion wary 7681 2
...IRE)--Mar 27, 2007 - Interleukin,Genetics, Inc. (A...lifornia San Diego today reported at the American ...ions between coronary artery,disease (CAD) and bot...ppear to be dependent on pro-inflammatory variants...tion titled "The Influence of Oxidized,Phospholipi...
...l for Vaccine Delivery System, NYON, Switzerland, ...Corporation announced today that the Company,s HIV...human primate model.,Mucosal IgA antibodies are co...infection by HIV. The data were presented by,Sylva...er in an,oral presentation, "Without Mucosal Adjuv...
Other Medicine Technology:ACC Presentation Indicates Interleukin-1 Gene Variants Determine,Increased Risk for Coronary Artery Disease from Oxidized,Phospholipids 2ACC Presentation Indicates Interleukin-1 Gene Variants Determine,Increased Risk for Coronary Artery Disease from Oxidized,Phospholipids 3Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting,Protective Antibody Response in Mucosal Tissues of Non-Human,Primate Model 2Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting,Protective Antibody Response in Mucosal Tissues of Non-Human,Primate Model 3Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting,Protective Antibody Response in Mucosal Tissues of Non-Human,Primate Model 4